CASI Pharma Acquires 29 Generic Drug Candidates from Sandoz

CASI Pharma, a US-China company, acquired a portfolio of 29 generic drugs from Sandoz, the generic drug division of Novartis. Each of the products has submitted Abbreviated New Drug Applications (ANDAs) for US approval. CASI, which will focus on bringing the generic drugs to China , will select members of the portfolio for development, emphasizing entecavir, an antiviral for hepatitis B. It may also manufacture the drugs in China for US use. The financial terms of the agreement were not disclosed. More details.... Stock Symbol: (NSDQ: CASI) (NYSE: NVS) Share this with colleagues: // //